THX Pharma
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ALTHX.PA research report →
About the company
Theranexus, a biopharmaceutical enterprise, specializes in the creation of potential medications for ailments affecting the central nervous system. Their primary investigational compound, THN102, is presently undergoing Phase II clinical evaluation for conditions related to sleep and wake cycles. Furthermore, they are developing THN201 to target neurocognitive challenges associated with Alzheimer's disease, and THN101 for the management of neuropathic discomfort.
- CEO
- Mathieu Charvériat
- IPO
- 2017
- Employees
- 12
- HQ
- Lyon, FR
Price Chart
- Market Cap
- $31.32M
- P/E
- -15.11
- P/S
- 38.34
- P/B
- 23.04
- EV/EBITDA
- -3.31
- Div Yield
- 0.00%
- Gross Margin
- -13.29%
- Op Margin
- -1251.59%
- Net Margin
- -367.39%
- ROE
- -6167.16%
- ROIC
- -120.30%
- Revenue
- $0 · -100.00%
- Net Income
- $-3,001,558 · -70.04%
- EPS
- $-0.22 · -4.76%
- Op Income
- $-10,225,452
- FCF YoY
- 72.37%
- 52W High
- $5.10
- 52W Low
- $0.80
- 50D MA
- $3.42
- 200D MA
- $2.70
- Beta
- 1.52
- Avg Volume
- 110.71K
Get TickerSpark's AI analysis on ALTHX.PA
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Our ALTHX.PA coverage
Recent articles, reports, and earnings notes.
No research on ALTHX.PA yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate ALTHX.PA report →Similar companies
Peers in the same neighborhood.